Drugs / Betalutin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03806179 | Oct 2018 → Aug 2022 | follicular lymphoma | Nordic Nanovector | Completed | No outcome recorded |
| Phase 1 | NCT02657447 | Dec 2017 → Sep 2019 | non-Hodgkin lymphoma | Nordic Nanovector | Withdrawn | No outcome recorded |
| Phase 1 | NCT02658968 | Mar 2017 → Jun 2021 | diffuse large B-cell lymphoma | Nordic Nanovector | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Betalutin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03806179 ↗ |
| Known as | lutetium (177Lu) lilotomab satetraxetan | “15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 1” NCT02657447 ↗ |